Pune-based Mylab Discovery Solutions has scaled up its production and development of COVID-19 pathodetect testing kit with the help of strategic funding under National Biopharma Mission of Department of Biotechnology (DBT)-Biotechnology Industry Research Assistance Council (BIRAC).
HasmukhRawal, MD, Mylab Discovery Solutions said, “We are very thankful to Biotechnology Industry Research Assistance Council for hand holding us when no one believed us. With the funds we would really be able to accelerate our process of the production”
Dr RenuSwarup, Secretary DBT and Chairperson BIRAC said “in our fight against the current pandemic, having indigenous supplies of qualitative RT-PCR test kits was identified as a critical need in enhancing the testing ability across the country. Therefore scale-up of Mylab’s pathodetect production was a step DBT took very early in that direction. This production line at Mylab manufactures rapid, high throughput detection platform and is aligned with our Hon’ble Prime Minister’s vision of AtmaNirbhar Bharat.”
Currently, Mylab has a manufacturing capacity of 2,00,000 RT-PCR and 50,000 RNA tests. Mylab has obtained CDSCO/India-FDA and ICMR approval to manufacture for NAT, HIV, HBV, HCV, and for detection of novel coronavirus 2019-n COV/SARS-COV-2.
The company has recently launched a Molecular laboratory machine Compact XL that can manufacture various reagents as well as perform many molecular tests in a single machine unit. The machine will help India in setting up the Molecular Diagnostic labs in rural India as it eliminates huge infrastructure costs, Capex and Opex costs since minimal number of employees can do a large number of tests.
The Department of Biotechnology (DBT), under the Ministry of Science & Technology, promotes and accelerates the development of biotechnology in India, including growth and application of biotechnology in the areas of agriculture, healthcare, animal sciences, environment and industry.
Biotechnology Industry Research Assistance Council (BIRAC) is a not-for-profit Section 8, Schedule B, Public Sector Enterprise, set up by Department of Biotechnology (DBT), Government of India as an Interface Agency to strengthen and empower the emerging Biotech enterprise to undertake strategic research and innovation, addressing nationally relevant product development needs
About National Biopharma Mission:
The Industry-Academia Collaborative Mission of Department of Biotechnology (DBT), Govt of India for accelerating discovery research to early development for Biopharmaceuticals approved by the Cabinet for a total cost US$ 250 million and 50% co-funded by the World Bank is being implemented at Biotechnology Research Assistance Council (BIRAC). This program is dedicated to deliver affordable products to the nation with an aim to improve the health standards of India’s population. Vaccines, medical devices and diagnostics and biotherapeutics are few of its most important domains, besides, strengthening the clinical trial capacity and building technology transfer capabilities in the country.
(For Further Information: Contact Communication Cell of DBT/BIRAC